Annual Immunology Workshop

Thank you to all 428 attendees for sharing your science with the IIG community. We’d also like to extend an extra thank you to our three gurus- Drs. Mariana Kaplan (NIAMS), Naomi Taylor (NCI), and Gregoire Altan-Bonnet (NCI)- for your expertise and active participation in the retreat. The IIG had the privilege of honoring Dr. Howard Young (NCI) for his 40+ year career and monumental discoveries involving interferons in inflammation and autoimmunity. We appreciate Howard’s continued support of the IIG.

Immunology Interest Group (IIG) Seminar Series

Immunologists and Immunology Interest Group Members

NIH-FDA Immunology Interest Group Events

NIH-FDA Immunology Interest Group Steering Committee

All Immunology Interest Group (IIG) activities are organized by the Steering Committee, whose members (that comprise senior investigators, tenure track investigators, staff scientists, postdoctoral fellows and graduate students) are elected annually by the entire IIG community.

2024-2025 IIG Steering Committee

* new committee members

NIH-FDA Immunology Interest Group (IIG)

The NIH-FDA Immunology Interest Group (IIG) organizes activities designed to promote information exchange and interactions among NIH and FDA scientists interested in the field of immunology. Interactions are facilitated via weekly meetings on current topics as well as an Annual Immunology Workshop. The IIG of the National Institutes of Health (NIH) and the Food and Drug Administration (FDA) is a voluntary organization of investigators and trainees who are members of the intramural research community of the NIH, FDA, and affiliated research and teaching organizations that promotes the mission of the NIH and FDA in research and training in the areas of immunology and infectious diseases. The IIG serves as the organizational structure for intramural researchers to promote high academic standards of research and training and foster the development of new biomedical knowledge and the translation of research knowledge into new preventive measures and therapies for human diseases by facilitating interdisciplinary and multidisciplinary research. The IIG was instituted in 1993. The IIG is the largest interest group on campus with over 500 active members in 19 different institutes and over 1000 subscribers to the list-serve.

Major Areas of Focus

The IIG sponsors two primary activities that are crucial to fostering interactions and promoting scientific communication among the NIH-FDA Immunology Community:

Oversight

All IIG activities are organized by the Steering Committee, whose members are elected annually by the entire IIG community. Steering Committee members comprise senior investigators, tenure track investigators, Staff scientists, Postdoctoral fellows and graduate students. See the current IIG Steering Committee members.

Contact Information

To join or leave the IIG listserv, IMMUNI-L, follow the instructions on the NIH Listserv. For the listserv, you must use the same email address that is listed in the NIH Enterprise Directory.

Events

The NIH-FDA Immunology Interest Group (IIG) organizes activities designed to promote information exchange and interactions among NIH and FDA scientists interested in the field of immunology. Interactions are facilitated via weekly meetings on current topics as well as an Annual Immunology Workshop.

2024-2025 Seminar Series
  • Lipsett Auditorium @ 4:00 ET
  • March 12: Oyebola Oyesola (NIAID)
  • March 19: Jing Wu or Anand Gupta (NHLBI)
  • March 26: Niki Moutsopoulos (NIAID)
Immunologists and IIG Members
Networks & Programs
No local navigation
Off

Questions and Answers for NIAID Investigator-Initiated Program Project Applications (P01, Clinical Trial Not Allowed)

Jenna R.E. Bergerson, M.D., M.P.H.

Staff Clinician
Associate Program Director, Allergy-Immunology Fellowship Training Program
Co-Director, Allergy-Immunology Consult Service
Deputy Director, Primary Immune Deficiency Clinic

Major Areas of Research

  • Diagnosis, natural history, and treatment of primary immune deficiency disorders and disorders of immune dysregulation

Biography

Jenna Bergerson, M.D. is an assistant research physician at NIAID. She has been involved in translational research in primary immune deficiencies and disorders of immune dysregulation since joining the Primary Immune Deficiency Clinic in 2017.

She received her M.D. from Tulane University School of Medicine. She completed a pediatric residency at Rainbow Babies & Children’s Hospital, Case Western University Medical Center in Cleveland, OH, followed by a fellowship in allergy and immunology at The Ann & Robert H. Lurie Children’s Hospital of Chicago, Northwestern University Medical Center. She also holds a master of public health degree from Tulane University School of Public Health. She is board certified in pediatrics and allergy-immunology and is a fellow of the American Academy of Allergy, Asthma, and Immunology (AAAAI) and the Clinical Immunology Society (CIS).

At NIH, she serves as the co-director of the Allergy-Immunology Consult Service, as the Deputy Director of the Primary Immune Deficiency Clinic, and on the NIAID inpatient-outpatient working group committee. Her external committee activities include involvement in the membership committee of the Clinical Immunology Society.

Program Description

Dr. Bergerson’s current research and clinical activities focus on seeing patients with a wide variety of primary immune deficiency disorders and primary disorders of immune dysregulation.

Selected Publications

Hsu AP, Donkó A, Arrington ME, Swamydas M, Fink D, Das A, Escobedo O, Bonagura V, Szabolcs P, Steinberg HN, Bergerson J, Skoskiewicz A, Makhija M, Davis J, Foruraghi L, Palmer C, Fuleihan RL, Church JA, Bhandoola A, Lionakis MS, Campbell S, Leto TL, Kuhns DB, Holland SM. Dominant activating RAC2 mutation with lymphopenia, immunodeficiency, and cytoskeletal defects. Blood. 2019 May 2;133(18):1977-1988.

Bergerson JRE, Freeman AF. An Update on Syndromes with a Hyper-IgE Phenotype. Immunol Allergy Clin North Am. 2019 Feb;39(1):49-61. doi: 10.1016/j.iac.2018.08.007. Review. PMID:30466772

Arts K, Bergerson JRE, Ombrello AK, Similuk M, Oler AJ, Agharahimi A, Mace EM, Hershfield M, Wouters C, De Somer L, Morren MA, Diego RP, Moens L, Freeman AF, Meyts I. Warts and DADA2: a Mere Coincidence? J Clin Immunol. 2018 Nov;38(8):836-843.

Jhamnani RD, Nunes-Santos CJ, Bergerson J, Rosenzweig SD. Class-Switch Recombination (CSR)/Hyper-IgM (HIGM) Syndromes and Phosphoinositide 3-Kinase (PI3K) Defects. Front Immunol. 2018 Sep 26;9:2172.

Gupta M, Aluri J, Desai M, Lokeshwar M, Taur P, Lenardo M, Bergerson J, Dalvi A, Mhatre S, Kulkarni M, Kambli P, Madkaikar M. Clinical, Immunological, and Molecular Findings in Four Cases of B Cell Expansion With NF-κB and T Cell Anergy Disease for the First Time From India. Front Immunol. 2018 Jun 14;9:1049.

Khanolkar A, Kirschmann DA, Caparelli EA, Wilks JD, Cerullo JM, Bergerson JRE, Jennings LJ, Fuleihan RL. CD4 T cell-restricted IL-2 signaling defect in a patient with a novel IFNGR1 deficiency. J Allergy Clin Immunol. 2018 Jan;141(1):435-439.e7.

Visit PubMed for a complete publication listing.

Training Program

Allergy and Immunology

Section or Unit Name
Primary Immune Deficiency Clinic
First Name
Jenna
Last Name
Bergerson
Middle Name
R.E.
Suffix
M.D., M.P.H.
Exclude from directory
Off
This Researcher/Clinician’s Person Page
Program Description

Dr. Bergerson’s current research and clinical activities focus on seeing patients with a wide variety of primary immune deficiency disorders and primary disorders of immune dysregulation.

Selected Publications

James AE, West L, Schloss K, Nataraj P, Urban A, Hirsch A, Krausz M, Kumar S, Raasch J, Risma K, Church JA, Grimbacher B, Bergerson JRE, Chong H, Freeman AF. Treatment of STAT3-deficient hyper-immunoglobulin E syndrome with monoclonal antibodies targeting allergic inflammation. J Allergy Clin Immunol Pract. 2022 May;10(5):1367-1370.e1.

Nunes-Santos CJ, Koh C, Rai A, Sacco K, Marciano BE, Kleiner DE, Marko J, Bergerson JRE, Stack M, Rivera MM, Constantine G, Strober W, Uzel G, Fuss IJ, Notarangelo LD, Holland SM, Rosenzweig SD, Heller T. Nodular regenerative hyperplasia in X-linked agammaglobulinemia: An underestimated and severe complication. J Allergy Clin Immunol. 2022 Jan;149(1):400-409.e3.

Delmonte OM, Bergerson JRE, Burbelo PD, Durkee-Shock JR, Dobbs K, Bosticardo M, Keller MD, McDermott DH, Rao VK, Dimitrova D, Quiros-Roldan E, Imberti L, Ferrè EMN, Schmitt M, Lafeer C, Pfister J, Shaw D, Draper D, Truong M, Ulrick J, DiMaggio T, Urban A, Holland SM, Lionakis MS, Cohen JI, Ricotta EE, Notarangelo LD, Freeman AF. Antibody responses to the SARS-CoV-2 vaccine in individuals with various inborn errors of immunity. J Allergy Clin Immunol. 2021 Nov;148(5):1192-1197.

Delmonte OM, Bergerson JRE, Kawai T, Kuehn HS, McDermott DH, Cortese I, Zimmermann MT, Dobbs AK, Bosticardo M, Fink D, Majumdar S, Palterer B, Pala F, Dsouza NR, Pouzolles M, Taylor N, Calvo KR, Daley SR, Velez D, Agharahimi A, Myint-Hpu K, Dropulic LK, Lyons JJ, Holland SM, Freeman AF, Ghosh R, Similuk MB, Niemela JE, Stoddard J, Kuhns DB, Urrutia R, Rosenzweig SD, Walkiewicz MA, Murphy PM, Notarangelo LD. SASH3 variants cause a novel form of X-linked combined immunodeficiency with immune dysregulation. Blood. 2021 Sep 23;138(12):1019-1033.

Hsu AP, Donkó A, Arrington ME, Swamydas M, Fink D, Das A, Escobedo O, Bonagura V, Szabolcs P, Steinberg HN, Bergerson J, Skoskiewicz A, Makhija M, Davis J, Foruraghi L, Palmer C, Fuleihan RL, Church JA, Bhandoola A, Lionakis MS, Campbell S, Leto TL, Kuhns DB, Holland SM. Dominant activating RAC2 mutation with lymphopenia, immunodeficiency, and cytoskeletal defects. Blood. 2019 May 2;133(18):1977-1988.

Arts K, Bergerson JRE, Ombrello AK, Similuk M, Oler AJ, Agharahimi A, Mace EM, Hershfield M, Wouters C, De Somer L, Morren MA, Diego RP, Moens L, Freeman AF, Meyts I. Warts and DADA2: a Mere Coincidence? J Clin Immunol. 2018 Nov;38(8):836-843

Visit PubMed for a complete publication listing.

Additional Information

Training Program

Allergy and Immunology Fellowship Program

NIAID offers a three-year training program in allergy and immunology. This program, open to physicians who have completed internal medicine and/or pediatric residency training, is designed to provide trainees with high-quality clinical and research skills that will enable them to successfully pursue careers in academic medicine. 

The NIAID Allergy and Immunology Clinical Fellowship Program is fully accredited by the Accreditation Council for Graduate Medical Education (ACGME). Fellows are eligible to sit for the Board of Allergy and Immunology certification examination after successful completion of the first two years of the program.

Major Areas of Research
  • Diagnosis, natural history, and treatment of primary immune deficiency disorders and disorders of immune dysregulation

Notice of Special Interest (NOSI) SOP

Cooperative Agreements (U)

A cooperative agreement (U) is a support mechanism we frequently use for high-priority research areas that require substantial involvement from NIH program or scientific staff.